19 Aug 2024
// PRESS RELEASE
14 Aug 2024
// GLOBENEWSWIRE
16 Apr 2024
// PRESS RELEASE
Latest Content by PharmaCompass
Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances & suspensions.
About
CPHI Middle eastCPHI Middle east
Industry Trade Show
Not Confirmed
10-12 December, 2024
Medlab Asia & Asia Hea...Medlab Asia & Asia Health
Industry Trade Show
Not Confirmed
24 November-17 July, 2025
Health 2.0 ConferenceHealth 2.0 Conference
Industry Trade Show
Not Confirmed
02-04 December, 2024
CONTACT DETAILS
Events
Webinars & Exhibitions
CPHI Middle eastCPHI Middle east
Industry Trade Show
Not Confirmed
10-12 December, 2024
Medlab Asia & Asia Hea...Medlab Asia & Asia Health
Industry Trade Show
Not Confirmed
24 November-17 July, 2025
Health 2.0 ConferenceHealth 2.0 Conference
Industry Trade Show
Not Confirmed
02-04 December, 2024
CORPORATE CONTENT #SupplierSpotlight
19 Aug 2024
// PRESS RELEASE
https://www.everpharma.com/news/ever-pharma-gained-eu-approval-of-testosterone-enantate/
14 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/14/2930389/0/en/Silo-Pharma-Expands-Development-Agreement-with-Sever-Pharma-for-Novel-Ketamine-Implant-Therapeutic.html
16 Apr 2024
// PRESS RELEASE
https://www.everpharma.com/news/ever-pharma-gained-eu-approval-for-advanced-cancer-treatment/
13 Mar 2024
// PRESS RELEASE
https://www.everpharma.com/news/ever-pharma-announces-approval-of-testosterone-undecanoate-in-the-eu/
22 Jun 2023
// PRESS RELEASE
https://www.everpharma.com/news/ever-pharma-gains-eu-marketing-authorization-for-trabectedin/
10 Mar 2023
// PRESS RELEASE
https://www.everpharma.com/news/ever-pharma-expands-operations-with-opening-of-new-manufacturing-facility-in-jena-germany/
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2018-07-20
Registration Number : 20180720-2-K-38-01
Manufacturer Name : Ever Neuro Pharma GmbH
Manufacturer Address : Oberburgau 3, A-4866 Unterach, Austria
Details:
Testosterone enantate EVER Pharma is an androgen receptor agonist indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency of endogenous testosterone.
Lead Product(s): Testosterone Enanthate
Therapeutic Area: Endocrinology Brand Name: Testosterone Enantate Ever Pharma
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 19, 2024
Lead Product(s) : Testosterone Enanthate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EVER Pharma Gained EU-Approval of Testosterone Enantate
Details : Testosterone enantate EVER Pharma is an androgen receptor agonist indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency of endogenous testosterone.
Brand Name : Testosterone Enantate Ever Pharma
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 19, 2024
Details:
Eribulin EVER Pharma is a microtubule inhibitor which is indicated for the treatment of locally advanced or metastatic breast cancer and unresectable liposarcoma.
Lead Product(s): Eribulin
Therapeutic Area: Oncology Brand Name: Eribulin EVER Pharma
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2024
EVER Pharma gained EU-Approval for Advanced Cancer Treatment
Details : Eribulin EVER Pharma is a microtubule inhibitor which is indicated for the treatment of locally advanced or metastatic breast cancer and unresectable liposarcoma.
Brand Name : Eribulin EVER Pharma
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 16, 2024
Details:
Testosterone undecanoate EVER Pharma is an androgen receptor agonist indicated for testosterone replacement therapy in males for conditions associated with a deficiency of endogenous testosterone.
Lead Product(s): Testosterone Undecanoate
Therapeutic Area: Endocrinology Brand Name: Testosterone Undecanoate EVER Pharma
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 13, 2024
Lead Product(s) : Testosterone Undecanoate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EVER Pharma Announces Approval of Testosterone Undecanoate in the EU
Details : Testosterone undecanoate EVER Pharma is an androgen receptor agonist indicated for testosterone replacement therapy in males for conditions associated with a deficiency of endogenous testosterone.
Brand Name : Testosterone Undecanoate EVER Pharma
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 13, 2024
Details:
EVER Pharma has received the EU-wide marketing authorization of Trabectedin EVER Pharma, which is available in 0.25mg and 1mg vial sizes for treating advanced soft tissue sarcoma and ovarian cancer.
Lead Product(s): Trabectedin
Therapeutic Area: Oncology Brand Name: Trabectedin EVER Pharma
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2024
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EVER Pharma gains EU Marketing Authorization for Trabectedin
Details : EVER Pharma has received the EU-wide marketing authorization of Trabectedin EVER Pharma, which is available in 0.25mg and 1mg vial sizes for treating advanced soft tissue sarcoma and ovarian cancer.
Brand Name : Trabectedin EVER Pharma
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 22, 2024
Details:
Bortezomib EVER Pharma is a proteasome inhibitor small molecule drug candidate, which is indicated for the treatment of patients with multiple myeloma and mantle cell lymphoma.
Lead Product(s): Bortezomib
Therapeutic Area: Oncology Brand Name: Bortezomib EVER Pharma
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2022
Lead Product(s) : Bortezomib
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EVER Pharma receives EU approval for a liquid ready to use Bortezomib formulation
Details : Bortezomib EVER Pharma is a proteasome inhibitor small molecule drug candidate, which is indicated for the treatment of patients with multiple myeloma and mantle cell lymphoma.
Brand Name : Bortezomib EVER Pharma
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 09, 2022
Details:
Azacitidine EVER Pharma is a DNMT1/DNMT3A indicated for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Lead Product(s): Azacitidine
Therapeutic Area: Oncology Brand Name: Azacitidine EVER Pharma
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2021
Lead Product(s) : Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EVER Pharma receives EU marketing authorization for Azacitidine
Details : Azacitidine EVER Pharma is a DNMT1/DNMT3A indicated for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Brand Name : Azacitidine EVER Pharma
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 12, 2021
Details:
EVER Pharma has received EU-wide marketing authorization of Pemetrexed EVER Pharma for the treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer.
Lead Product(s): Pemetrexed
Therapeutic Area: Oncology Brand Name: Pemetrexed EVER Pharma
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2020
Lead Product(s) : Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EVER Pharma gains EU marketing authorization for value-added Pemetrexed
Details : EVER Pharma has received EU-wide marketing authorization of Pemetrexed EVER Pharma for the treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer.
Brand Name : Pemetrexed EVER Pharma
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 15, 2020
Details:
Cabazitaxel EVER Pharma in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer.
Lead Product(s): Cabazitaxel,Prednisone
Therapeutic Area: Oncology Brand Name: Cabazitaxel EVER Pharma
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Lead Product(s) : Cabazitaxel,Prednisone
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EVER Pharma gains EU marketing authorization for value-added Cabazitaxel
Details : Cabazitaxel EVER Pharma in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer.
Brand Name : Cabazitaxel EVER Pharma
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 21, 2020
Services
Drug Product Manufacturing
Pharma Service : Drug Product Manufacturing
Category : Solution
Sub Category : Injectable
Pharma Service : Drug Product Manufacturing
Pharma Service : Drug Product Manufacturing
Category : Suspension
Sub Category : Injectable
Pharma Service : Drug Product Manufacturing
Pharma Service : Drug Product Manufacturing
Category : Liquid
Sub Category : Clinical Supply
Pharma Service : Drug Product Manufacturing
Pharma Service : Drug Product Manufacturing
Category : Liquid
Sub Category : Controlled Substance
Pharma Service : Drug Product Manufacturing
Pharma Service : Drug Product Manufacturing
Category : Liquid
Sub Category : High Potency APIs (HPAPIs)
Pharma Service : Drug Product Manufacturing
Pharma Service : Drug Product Manufacturing
Pharma Service : Drug Product Manufacturing
Pharma Service : Drug Product Manufacturing
Category : Injectable / Parenteral
Sub Category : Overview
Pharma Service : Drug Product Manufacturing
Pharma Service : Drug Product Manufacturing
Category : Injectable / Parenteral
Sub Category : Controlled Substance
Pharma Service : Drug Product Manufacturing
Pharma Service : Drug Product Manufacturing
Category : Injectable / Parenteral
Sub Category : High Potency APIs (HPAPIs)
Pharma Service : Drug Product Manufacturing
Pharma Service : Drug Product Manufacturing
Category : Injectable / Parenteral
Sub Category : Steroid / Hormone
Pharma Service : Drug Product Manufacturing
Pharma Service : Drug Product Manufacturing
Category : Injectable / Parenteral
Sub Category : Pre-Filled Syringe
Pharma Service : Drug Product Manufacturing
API & Drug Product Development
Pharma Service : API & Drug Product Development
Category : Formulation Development
Sub Category : Process Development & Optimization
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Category : Formulation Development
Sub Category : Injectable / Parenteral
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Category : Formulation Development
Sub Category : Controlled Substance
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Category : Formulation Development
Sub Category : Process Validation Studies
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Category : Formulation Development
Sub Category : Sterile Liquid Formulation
Pharma Service : API & Drug Product Development
Pharma Service : API & Drug Product Development
Category : Formulation Development
Sub Category : Steroid / Hormone
Pharma Service : API & Drug Product Development
Inspections and registrations
Type : GMP Certificates
Number : DE_TH_01H_G...
EudraGMDP Key : 170739
Country : Germany
Issue Date : 2024-07-02
Post Code :
NCA Ref : 217687171996...
City : Jena
Type : GMP Certificates
Number : DE_TH_01H_G...
EudraGMDP Key : 170740
Country : Germany
Issue Date : 2024-07-02
Post Code :
NCA Ref : 217688171996...
City : Jena
Type : GMP Certificates
Number : 482197-1418...
EudraGMDP Key : 143779
Country : Austria
Issue Date : 2021-12-22
Post Code :
NCA Ref : 482197
City : Unterach am Attersee
Type : GMP Certificates
Number : 482167-1418...
EudraGMDP Key : 150878
Country : Austria
Issue Date : 2021-12-22
Post Code :
NCA Ref : 482167
City : Ebensee
Type : GMP Certificates
Number : 482197-0045
EudraGMDP Key : 52731
Country : Austria
Issue Date : 2019-02-04
Post Code :
NCA Ref : 482197
City : Unterach am Attersee
Type : GMP Certificates
Number : 482167-0009
EudraGMDP Key : 52732
Country : Austria
Issue Date : 2018-11-20
Post Code :
NCA Ref : 482167
City : Ebensee
Type : GMP Certificates
Number : 482197-0028
EudraGMDP Key : 34259
Country : Austria
Issue Date : 2015-12-03
Post Code :
NCA Ref : 482197
City : Unterach am Attersee
Type : GMP Certificates
Number : 482197-0025
EudraGMDP Key : 24478
Country : Austria
Issue Date : 2014-06-26
Post Code :
NCA Ref : 482197
City : Unterach am Attersee
Type : GMP Certificates
Number : 482197-0011
EudraGMDP Key : 21346
Country : Austria
Issue Date : 2013-09-11
Post Code :
NCA Ref : 482197
City : Unterach am Attersee
Type : GMP Certificates
Number : 482167-0004
EudraGMDP Key : 15764
Country : Austria
Issue Date : 2012-09-25
Post Code :
NCA Ref : 482167
City : Ebensee
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?